Safety and Tolerability of FMT Capsules in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-21

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a two-part, randomized, double-blind, placebo-controlled, single center study to investigate the safety and tolerability of XBI-302 administered orally in healthy volunteers. The hypothesis of this study is that XBI-302 is safe and well tolerated with the proposed dosing regimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization

NCT04746222

Carbapenem-Resistant Enterobacteriaceae Infection

UNKNOWN PHASE2/PHASE3

Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity

NCT00772954

Clostridium Difficile Infection Clostridium Difficile Diarrhea

TERMINATED PHASE1

Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics

NCT07261826

Clostridium Difficile Infection Recurrence Ulcerative Colitis (UC) Crohn Disease (CD) +6 more

RECRUITING

Pilot Study Using Oral Capsule FMT to Decolonize GI CRE

NCT03527056

Enterobacteriaceae Infections Fecal Microbiota Transplantation

WITHDRAWN EARLY_PHASE1

Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum

NCT02343328

Clostridium Difficile

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute-graft-versus-host Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Intervention Type BIOLOGICAL

XBI-302 Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XBI-302

Fecal Microbiota Transplantation Capsules

Intervention Type BIOLOGICAL

XBI-302 Placebo

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willing to participate and sign the ICF.
2. Healthy adults 18-55 years of age, male and female.
3. For women of childbearing age, negative serum pregnancy test at Screening and negative serum pregnancy test confirmed at the admission to the Phase 1 unit.
4. Female participants must not be pregnant, lactating, or actively trying to become pregnant. Participants who are premenopausal and of childbearing potential must have two negative pregnancy tests (serum) and both female and male participants must use medically acceptable and effective contraceptive methods during the study period, including:

1. Having a male partner who is sterile prior to the female participant's entry into the study and is the sole sexual partner for that female participant
2. Use of double-barrier methods of contraception; condoms with the use of caps (with spermicide) and intra-uterine devices are acceptable
3. True abstinence, when this is in line with the preferred and usual lifestyle of the participant (Note: period abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception)
5. Clinical laboratory test values (hematology, blood chemistry, routine stool test, urinalysis, etc.) are in the normal ranges or although it was outside the normal limits, the researchers determined that the participant will still be eligible within the screening period.
6. Participants have a body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m2) inclusive, and a body weight of at least 45 kilograms (kg).

Exclusion Criteria

1. History of cardiovascular disease, immune system disease, malignant disease such as cancer, nervous system disease, hematological disease, endocrinological disease, and/or any other diseases that in the opinion of the investigator could impact assessments of safety or the gut microbiome.
2. Significant past medical history of GI conditions including inflammatory bowel disease, irritable bowel syndrome, celiac disease, history of GI malignancy or polyposis, C. difficile infection in past year.
3. GI symptoms that occur more than four times a month including acid reflux, nausea, vomiting, diarrhea, abdominal pain or cramps, abdominal distension, bloating, constipation.
4. Used oral antibiotics within 4 weeks prior to the first FMT dosing.
5. HIV infection and/or HBV/HCV infection.
6. Active tuberculosis and undergoing treatment.
7. History of mental illness, drug or alcohol abuse and/or any other behavioral issues that may impact study compliance.
8. Lactating women or participants who plan to become pregnant or conceive within half a year.
9. History of severe hypersensitivity (may cause difficulty in breathing).
10. Alcohol breathalyzer test positive, urine drug screening test positive, and/or smoker.
11. Participated in any other clinical trials within 3 months of first dose.
12. Participants with history of bowel or gastrointestinal surgery.
13. Participants who are immunosuppressed or immunocompromised, either by genetic, acquired or secondary to medication.
14. Participants who are experiencing symptoms associated with COVID-19 (including but not limited to cough, fever, shortness of breath, nausea, diarrhea, anhedonia, anosmia, ageusia or severe fatigue).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes